Please join us for a Celgene presentation of REVLIMID® in the treatment of del(5q) myelodysplastic syndromes (MDS). Sandra Kurtin, RN, MS, AOCN, ANP-C, from the University of Arizona Cancer Center will walk you through an overview of MDS, discuss considerations for the treatment of patients with MDS, present patient cases, and review the use of REVLIMID and important safety information. We are looking forward to your attendance.
